Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Magnetic Resonance Spectroscopy: Advanced Techniques And Applications In Metabolic Assessment

NOV 17, 202664 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate Magnetic Resonance Spectroscopy (CP-MRS) represents a non-invasive analytical technique enabling real-time quantification of high-energy phosphate metabolites in living tissues. By leveraging 31P-MRS and complementary multinuclear approaches, CP-MRS provides critical insights into cellular bioenergetics, particularly in myocardial and skeletal muscle tissues where phosphocreatine (PCr) serves as the primary energy buffer. This technology has evolved from basic spectral acquisition to sophisticated spatially resolved imaging modalities, integrating chemical shift imaging (CSI) principles with advanced correction algorithms to achieve quantitative metabolic profiling under physiological and pathological conditions 1,8,11.
Want to know more material grades? Try Patsnap Eureka Material.

Fundamental Principles Of Creatine Phosphate Magnetic Resonance Spectroscopy

Creatine Phosphate Magnetic Resonance Spectroscopy operates on the principle that atomic nuclei with unpaired protons or neutrons exhibit magnetic properties when placed in an external magnetic field 5,10. The technique specifically targets 31P nuclei present in phosphocreatine molecules, which resonate at characteristic Larmor frequencies distinct from other phosphate-containing metabolites such as adenosine triphosphate (ATP), inorganic phosphate (Pi), and phosphomonoesters 9.

The chemical shift phenomenon—whereby electron clouds surrounding nuclei alter the local magnetic field—enables differentiation of PCr from other phosphorus-containing compounds in biological tissues 5. Modern CP-MRS implementations achieve spectral resolution sufficient to distinguish PCr peaks (typically appearing at approximately -2.5 ppm relative to PCr reference) from ATP resonances (γ-ATP at -2.5 ppm, α-ATP at -7.5 ppm, β-ATP at -16.3 ppm) and Pi (appearing at chemical shifts dependent on intracellular pH, typically 4.5-5.5 ppm) 1,9.

Key technical parameters governing CP-MRS sensitivity include:

  • Magnetic field strength: Clinical systems operate at 1.5T to 7T, with higher fields providing improved signal-to-noise ratio (SNR) but increased susceptibility artifacts 8,11
  • Radiofrequency coil design: Surface coils provide optimal sensitivity for superficial tissues (penetration depth approximately equal to coil radius), while volume coils enable whole-organ coverage with reduced spatial resolution 9
  • Pulse sequence selection: Free induction decay (FID) acquisition offers maximum sensitivity, while spin-echo sequences provide improved spectral quality through J-coupling refocusing 11
  • Repetition time (TR): Typically 2-4 seconds to allow T1 relaxation of 31P nuclei (T1 values: PCr ~4-6 s, ATP ~2-3 s in muscle at 1.5T) 1

The spatial localization challenge inherent to surface coil spectroscopy—where the sensitive volume encompasses multiple tissue types—has driven development of chemical shift imaging (CSI) methodologies that enable voxel-wise metabolite quantification 8,11.

Chemical Shift Imaging Integration For Spatially Resolved Creatine Phosphate Quantification

Chemical Shift Imaging (CSI) extends conventional MRS by incorporating phase-encoding gradients to achieve spatial discrimination of metabolite distributions 8,11. In CP-MRS applications, CSI protocols typically employ two- or three-dimensional phase encoding schemes to generate metabolite maps with voxel dimensions of 5-15 mm isotropic resolution 11.

The CSI acquisition workflow for creatine phosphate mapping comprises:

  1. Volume pre-selection: Application of slice-selective excitation pulses (90° or Ernst angle) to define the imaging volume, often combined with outer volume suppression to eliminate contaminating signals from subcutaneous fat 8
  2. Phase encoding: Systematic variation of gradient amplitudes in two or three spatial dimensions across successive acquisitions, with encoding steps typically ranging from 8×8 to 32×32 matrices 11
  3. Signal acquisition: Recording of free induction decay (FID) signals with spectral bandwidth of 2-5 kHz and acquisition duration of 200-500 ms 8
  4. Fourier transformation: Multi-dimensional FFT processing to generate spatially resolved spectra, followed by peak fitting algorithms (e.g., AMARES, LCModel) to quantify individual metabolite concentrations 11

A critical innovation described in recent patent literature addresses the challenge of regional field inhomogeneity and susceptibility variations that produce spatially dependent line broadening and frequency shifts 8,11. The method involves convoluted acquisition of both metabolite signals and reference signals (typically from water or phosphate standards) with identical spatial encoding, enabling voxel-wise correction of local magnetic field imperfections 8. This approach achieves standardized, comparable results across different anatomical regions without substantially prolonging acquisition time—a crucial consideration for clinical translation 11.

Quantitative accuracy in CSI-based CP-MRS requires careful attention to:

  • Partial volume effects: Voxels at tissue boundaries contain mixed signal contributions; point-spread function deconvolution algorithms can mitigate this artifact 8
  • T1 and T2 relaxation corrections: Metabolite concentrations must be corrected for differential relaxation rates (PCr T2 ~150-200 ms, ATP T2 ~50-80 ms in muscle at 3T) 1
  • Coil sensitivity profiling: B1 field mapping enables correction of spatially varying excitation and reception efficiency 11

Multinuclear Approaches: Integrating 31P-MRS With 129Xe And 1H Spectroscopy

Advanced metabolic assessment increasingly employs multinuclear MRS strategies that combine 31P spectroscopy for energy metabolism with complementary nuclei providing orthogonal physiological information 1. A particularly innovative approach integrates 31P-MRS measurement of phosphocreatine with 129Xe-MRS assessment of blood flow perfusion to derive blood flow-dependent energy metabolism parameters 1.

The multinuclear protocol operates as follows:

  1. Simultaneous acquisition: Interleaved 31P and 129Xe CSI sequences acquire spatially matched datasets, with 31P providing PCr concentration maps and 129Xe (following hyperpolarization and inhalation) yielding red blood cell perfusion efficiency maps 1
  2. Stimulation paradigm: Subjects undergo physiological or pharmacological stimulation (e.g., visual stimulation for brain studies, exercise for muscle studies) to perturb metabolic-hemodynamic coupling 1
  3. Response quantification: Post-stimulation changes in PCr concentration (ΔPCr) are normalized to changes in RBC perfusion (ΔRBC) to calculate blood flow-dependent metabolic response parameters 1
  4. Parametric mapping: Voxel-wise calculation generates spatial maps of metabolic-hemodynamic coupling efficiency, revealing regional variations in energy supply-demand matching 1

This approach addresses a fundamental limitation of conventional 31P-MRS: the inability to distinguish whether observed PCr changes reflect altered metabolic demand, compromised substrate delivery, or mitochondrial dysfunction 1. By simultaneously quantifying perfusion, the method enables mechanistic differentiation of these scenarios.

Alternative multinuclear strategies employ 1H-MRS to measure creatine (Cr) and phosphocreatine indirectly through total creatine quantification 6. While 1H detection offers superior sensitivity compared to 31P (approximately 16-fold higher gyromagnetic ratio), it cannot directly distinguish PCr from free creatine, necessitating assumptions about the PCr/Cr ratio (typically ~2:1 in resting muscle) 6. Nonetheless, 1H-MRS enables non-invasive longitudinal monitoring of total creatine pool size, valuable for assessing creatine transporter function and evaluating creatine supplementation interventions 6.

Quantitative Metabolite Concentration Determination From Creatine Phosphate MRS Data

Absolute quantification of phosphocreatine concentration from MRS data requires addressing three fundamental challenges: (i) establishing signal proportionality to metabolite concentration, (ii) determining the tissue volume contributing to the signal, and (iii) calibrating the proportionality constants 9.

A validated quantification methodology employs a dual-phantom approach 9:

Subject Acquisition Phase:

  • Acquire 31P-MRS signal from PCr in the tissue of interest (e.g., myocardium, skeletal muscle)
  • Acquire 1H-MRS signal from tissue water in the same volume using identical coil positioning and acquisition geometry
  • Record signal amplitudes: S_PCr(subject) and S_H2O(subject)

Phantom Calibration Phase:

  • Replace subject with test phantom containing known concentrations of water (C_H2O,phantom) and phosphate reference standard (C_PO4,phantom) with identical 31P resonance characteristics to PCr
  • Acquire 31P and 1H signals using identical pulse sequences: S_PO4(phantom) and S_H2O(phantom)

Concentration Calculation: The tissue volume contributing to the PCr signal is deduced from:

V_tissue = V_phantom × [S_H2O(subject) / S_H2O(phantom)] × [C_H2O,phantom / C_H2O,tissue]

where C_H2O,tissue represents the known water concentration in the tissue type (typically 75-80% for muscle, corresponding to ~42-44 M) 9.

The absolute PCr concentration is then calculated as:

[PCr] = [S_PCr(subject) / S_PO4(phantom)] × [S_H2O(phantom) / S_H2O(subject)] × C_PO4,phantom × [C_H2O,tissue / C_H2O,phantom]

This method circumvents the problematic requirement for accurate tissue volume determination from MR images, which is particularly challenging for organs with complex geometry and motion (e.g., heart) 9. Typical PCr concentrations measured by this approach in healthy human skeletal muscle range from 25-35 mM, while myocardial PCr concentrations are 8-12 mM 9.

Critical experimental considerations for quantitative accuracy include:

  • Relaxation correction: Signals must be corrected for T1 saturation effects using measured or literature T1 values; incomplete relaxation (TR < 5×T1) requires correction factor: 1 / [1 - exp(-TR/T1)] 9
  • Coil loading effects: Phantom and subject must present similar electrical loading to the RF coil to maintain constant Q-factor and sensitivity 9
  • Temperature control: Phantom measurements should be performed at physiological temperature (37°C) as relaxation times and chemical shifts exhibit temperature dependence 9

Chemical Exchange Saturation Transfer (CEST) Enhancement Of Creatine Detection

Chemical Exchange Saturation Transfer (CEST) represents an emerging contrast mechanism that amplifies detection sensitivity for metabolites containing exchangeable protons, including creatine 2. The CEST technique exploits the chemical exchange between labile protons on the creatine guanidinium group (–NH2) and bulk water protons 2.

The CEST acquisition protocol involves:

  1. Selective saturation: Application of radiofrequency irradiation at the resonance frequency of creatine amine protons (typically +1.8 to +2.0 ppm from water) with B1 power levels of 0.5-3.0 μT and duration of 1-5 seconds 2
  2. Magnetization transfer: Saturated creatine protons exchange with water protons, transferring saturation to the bulk water pool and reducing water signal intensity 2
  3. Water imaging: Rapid gradient-echo or spin-echo imaging captures the attenuated water signal 2
  4. CEST ratio calculation: CESTR = (S_0 - S_sat) / S_0, where S_0 is the water signal without saturation and S_sat is the signal with creatine-selective saturation 2

The CEST effect magnitude depends critically on the chemical exchange rate (k_sw) between creatine and water, which exhibits pH dependence according to base-catalyzed exchange kinetics 2. This pH sensitivity enables simultaneous mapping of creatine concentration and tissue pH through power-ratiometric CEST (PRICEST) analysis 2.

PRICEST methodology acquires CEST data at multiple B1 power levels (e.g., 0.5, 1.0, 2.0, 3.0 μT) and fits the power-dependent CESTR to a two-pool exchange model, extracting:

  • Labile proton fraction (f_r): Proportional to creatine concentration, with f_r = [Cr] × n_exchangeable / [H2O], where n_exchangeable = 4 for creatine 2
  • Exchange rate (k_sw): Related to pH through k_sw = k_base × [OH⁻] + k_acid × [H⁺] + k_water, enabling pH mapping with precision of ±0.1-0.2 pH units 2

Validation studies using creatine phantoms demonstrate linear correlation between f_r and creatine concentration (r² > 0.98) across physiologically relevant ranges (10-50 mM), with pH sensitivity spanning pH 5.5-7.5 2. The technique offers potential advantages over conventional 31P-MRS for creatine assessment:

  • Enhanced sensitivity: CEST leverages the abundant water signal (~80 M protons) rather than direct detection of dilute metabolites (~30 mM), potentially improving SNR by 10-100 fold 2
  • Spatial resolution: CEST imaging can achieve sub-millimeter resolution using standard 1H MRI sequences, compared to typical 5-10 mm resolution for 31P-MRS 2
  • Simultaneous pH mapping: Provides complementary information about tissue acidosis, relevant for ischemia and tumor metabolism 2

However, CEST quantification faces challenges including magnetization transfer (MT) contamination from semi-solid macromolecules, B0 and B1 field inhomogeneity artifacts, and complex multi-pool exchange dynamics requiring sophisticated modeling 2.

Applications In Cardiovascular Disease Assessment And Therapeutic Monitoring

Creatine phosphate MRS has established particular clinical utility in cardiovascular disease evaluation, where myocardial PCr depletion serves as a biomarker of energetic impairment 6,7,9. The creatine kinase (CK) reaction—PCr + ADP + H⁺ ↔ Cr + ATP—functions as the primary temporal energy buffer in cardiomyocytes, maintaining ATP homeostasis during fluctuating workload 6.

Myocardial Infarction And Ischemia Detection

31P-MRS studies in patients with acute myocardial infarction demonstrate significant PCr depletion in infarcted territories, with PCr/ATP ratios declining from normal values of 1.8-2.2 to 0.5-1.0 in severely ischemic regions 9. The spatial extent of PCr reduction correlates with infarct size measured by radionuclide imaging, though correlation strength varies across studies due to methodological differences in volume localization 9.

Critically, PCr depletion precedes irreversible cellular injury, creating a therapeutic window for intervention 7. The PCr/ATP ratio exhibits stress-induced changes that may differentiate salvageable from non-salvageable myocardium: viable but hibernating myocardium shows preserved resting PCr/ATP with abnormal stress response, while infarcted tissue demonstrates persistently low ratios 9.

Creatine Transporter Upregulation As Therapeutic Strategy

Emerging therapeutic approaches target enhancement of myocardial creatine content through creatine transporter (CrT, SLC6A8) upregulation 6. The rationale derives from observations that increased intracellular creatine pool size augments the CK energy buffering capacity, potentially protecting against ischemic injury 6.

Screening methodologies for CrT-modulating compounds employ:

  • In vitro assays: Measurement of ¹⁴C-creatine uptake in cultured cardiomyoc
OrgApplication ScenariosProduct/ProjectTechnical Outcomes
INNOVATION ACADEMY FOR PRECISION MEASUREMENT SCIENCE AND TECHNOLOGY CASNon-invasive assessment of cerebral and myocardial energy metabolism under physiological stimulation, differentiating metabolic demand alterations from substrate delivery impairment in brain and cardiac tissues.Multinuclear MR Spectroscopy SystemIntegrates 31P-MRS for phosphocreatine quantification with 129Xe-MRS for blood flow perfusion assessment, enabling blood flow-dependent energy metabolism parameter mapping through normalized metabolic-hemodynamic coupling analysis.
The General Hospital CorporationQuantitative metabolic profiling in tissues requiring high spatial resolution creatine and pH assessment, including tumor metabolism evaluation and ischemia detection with sub-millimeter resolution imaging.PRICEST pH Mapping SystemAchieves simultaneous creatine concentration and pH mapping using power-ratiometric CEST analysis at multiple B1 levels (0.5-3.0 μT), providing pH precision of ±0.1-0.2 units with 10-100 fold SNR enhancement over conventional 31P-MRS.
ISIS INNOVATION LIMITEDPrevention and treatment of cardiovascular diseases through enhanced myocardial creatine buffering capacity, applicable to ischemia-reperfusion injury and chronic heart failure management.Creatine Transporter Upregulation TherapyUtilizes 1H-MRS for non-invasive longitudinal monitoring of myocardial creatine concentration changes, enabling in vivo dose-response studies and validation of creatine transporter modulating compounds for cardioprotection.
KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITÄT FREIBURGSpatially resolved phosphocreatine mapping in tissues with complex geometry and heterogeneous magnetic susceptibility, including skeletal muscle energy metabolism assessment and multi-organ metabolic profiling.CSI Field Correction SystemImplements convoluted acquisition of metabolite and reference signals with identical spatial encoding, enabling voxel-wise correction of regional field inhomogeneity and susceptibility variations without substantially prolonging acquisition time.
GENERAL ELECTRIC COMPANYQuantitative assessment of high-energy phosphate metabolites in organs with complex geometry and motion, particularly myocardial ATP and PCr concentration measurement for ischemic heart disease evaluation.Dual-Phantom Quantification MethodEmploys water reference normalization technique to determine absolute phosphocreatine concentrations (25-35 mM in skeletal muscle, 8-12 mM in myocardium) without requiring accurate tissue volume determination from MR images.
Reference
  • Multi-nuclear magnetic resonance method and device for evaluating blood flow dependent energy metabolism
    PatentActiveCN119147572A
    View detail
  • System and method for measuring pH using magnetic resonance
    PatentActiveUS10001536B2
    View detail
  • Process for the preparation of creatine phosphate
    PatentInactiveUS3639211A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png